Alzamend Neuro, Inc. · NASDAQ:ALZN
Alzamend Neuro — IPO Roadshow (May 2021)
21 slides from Alzamend Neuro's IPO roadshow presentation, May 28, 2021
Slide 1: Alzamend Neuro, Inc. Issuer Free Writing Prospectus
Alzamend Neuro, Inc.Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Registration Statement File No. 333-255955Ma¹ y 2021
Slide 2: Free Writing Prospectus Statement
FREE WRITING PROSPECTUS STATEMENT This presentation highlights basic information about us and the offering to which this presentation relates. Because it is a summary, it does not contain all of the information that you should consider before investing in our securities. Alzamend Neuro, Inc. (the “C
Slide 3: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Litigation Securities Litigation Reform Act of 1995. Those statements include, but are not limited to, statements with respect to
Slide 4: Table of Contents
TABLE OF CONTENTSIntroduction Company Overview 5 Alzheimer’s Disease (“AD”) 6Overview of Alzheimer’s DiseaseOur ScienceSpecific DetailsFinal DetailsEconomic Burden 7 Therapeutic Landscape 8 General Scientific Overview 9 AL001 (LiProSal™) 10-12 AL002 (CAO22W) 13 Intellectual Property (Licensed Patent
Slide 5: Introduction: Company Overview
INTRODUCTION Company OverviewCompany history Current projectsPreclinical stage biopharmaceutical company dedicated to: • Researching, developing and commercializing preventions, treatments and cures for neurodegenerative diseases and psychiatric disorders. • Working on two therapeutics licensed from
Slide 6: Overview of Alzheimer's Disease
OVERVIEW OF ALZHEIMER’S DISEASE Alzheimer’s DiseaseKey Statistics: 6th leading cause of death in the United States Every 65 seconds someone in the United States develops Alzheimer’s Disease13 million Americans are projected to be living with Alzheimer’s Disease by 20501-in-9 Americans over the age o
Slide 7: Overview of Alzheimer's Disease: Economic Burden
OVERVIEW OF ALZHEIMER’S DISEASE Economic Burden11. 2021 Alzheimer’s Disease Facts and Figures from the Alzheimer’s Association (www.alz.org/alzheimers-dementia/facts-figures)Important Implications 1. In 2021, the estimated healthcare costs for treating individuals with Alzheimer’s Disease in the Uni
Slide 8: Overview of Alzheimer's Disease: Therapeutic Landscape
OVERVIEW OF ALZHEIMER’S DISEASE Therapeutic Landscapehttps://alz-journals.onlinelibrary.wiley.com/cms/asset/006b182a-0807-477d-99bd-45d8c5306665/trc21205 0-gra-0001-m.jpg Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. 8
Slide 9: Our Science: General Scientific Overview
OUR SCIENCE General Scientific OverviewTherapeutic DrugAL001Synopsis▪ Use of patented Ionic Cocrystal (ICC) technology delivering a therapeutic combination of Lithium, Proline, and Salicylate ▪ Lithium as a treatment that may greatly reduce or eliminate the symptoms and biomarkers for mild to modera
Slide 10: Our Science: AL001 (LiProSal)
OUR SCIENCE AL001 (LiProSal)Plasma Lithium Levels 14 12 10 8 6 4Lithium salicylate (salt)L-proline (amino acid coformer)Ionic cocrystal (AL001)• Carbonate chemical form of lithium produces a plasma lithium spike thought to be associated with adverse events • Narrow therapeutic window that requires r
Slide 11: Our Science: AL001 (LiProSal) Preclinical Results
OUR SCIENCE AL001 (LiProSal)Preclinical studies concluded that low doses of AL001 are safe and effective in reducing Alzheimer’s Disease pathology:• AL001 had no effect on renal COX2 activity (Tg-Ctrl vs. AL001: p > 0.05), a biomarker of renal toxicity, while markedly reducing abnormal biomarkers as
Slide 12: Our Science: AL001 (LiProSal) Study and Results
OUR SCIENCE AL001 (LiProSal)• With the goal of improving lithium’s therapeutic profile, we investigated the safety, pharmacokinetics, and therapeutic efficacy of LiProSal (LP), compared with lithium carbonate (LC) and lithium salicylate (LS) across a host of preclinical models of AD. • Female APPSWE
Slide 13: Our Science: AL002 (CAO22W)
OUR SCIENCE AL002 (CAO22W)A cell-based therapeutic vaccine which seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s Diseasebeta-amyloid plaquesHypothesis: ▪ AL002 is intended to elicit an immune response to produce anti-amyloid antibodies, which can then neutral
Slide 14: Intellectual Property (Licensed Patents)
SPECIFIC DETAILS Intellectual Property (Licensed Patents)Title of PatentPatent TypeTherapeutic DrugDate FiledDate IssuedExpiration DateApplication/Patent #Lithium Cocrystals and an Additional Neuropsychiatric Agent for Treatment of Neuropsychiatric DisordersOrganic Anion Lithium Ionic Cocrystal Comp
Slide 15: Recent IPOs of Biotechnology Companies with AD Indication
SPECIFIC DETAILS Recent IPOs of Biotechnology Companies with AD IndicationCompanyScience/ TreatmentUse of FundsEmployeesIPO DateIPO PriceIPO ProceedsTotal SharesIPO ValuationAthira PharmaAnnovis BioCortexymeAlectorDenaliAlzheimer’s + NeurodegenerationAlzheimer’s + NeurodegenerationAlzheimer’s + Neur
Slide 16: Use of Proceeds
FINAL DETAILS Use of ProceedsDescriptionAmountOver-allotmentPhase I Clinical Trials for AL001$5,300,000$5,300,000Phase I Clinical Trials for Phase I AL002$3,600,000$3,600,000AL001 IND Filing License Fee$65,000$65,000AL001 Dosing First Patient License Fee$190,000$190,000AL002 IND Filing License Fee$5
Slide 17: IPO Terms
FINAL DETAILS IPO TermsTotal offering Price per share Number of shares Shares outstandingDescriptionAmount $12,500,000 $5.00 2,500,000 67,429,525Over-allotment $14,375,000 $5.00 2,875,000 67,429,525Conversion of Series A Preferred Shares after completion of IPO Gross proceeds from Digital Power Lend
Slide 18: Alzamend Leadership Team
FINAL DETAILS Alzamend Leadership TeamStephan Jackman Chief Executive Officer and Director 20+ years multi-industry experience, specialized in Biotech and PharmaceuticalKenneth S. Cragun Chief Financial Officer 30+ Years SEC reporting, CFO of publicly- traded company on Nasdaq, multi-industry experi
Slide 19: Alzamend Board of Directors
FINAL DETAILS Alzamend Board of DirectorsWilliam B. Horne Chairman of Alzamend Chief Executive Officer of Ault Global Holding 25+ years Financial Industry experience, prior “Big 4” auditor and healthcare executiveStephan Jackman Chief Executive Officer and Director 20+ years multi-industry experienc
Slide 20: Alzamend Scientific Advisory Board
FINAL DETAILS Alzamend Scientific Advisory BoardEric McDade, DO Associate Director of the Dominantly Inherited Alzheimer Network Trials Unit (“DIAN-TU”), Washington University School of Medicine 76+ Peer-Reviewed Journal Publications Leads a Research Laboratory Continuously Funded by the National In
Slide 21: For more information please contact
For more information please contact: Stephan Jackman Chief Executive Officer sjackman@alzamend.comFiled Pursuant to Rule 433 Issuer Free Writing Prospectus Registration Statement File No. 333-255955M²a¹ y 2021